Left Bundle Branch vs Right Ventricular Pacing for Heart Block
Trial Summary
What is the purpose of this trial?
High burden right ventricular (RV) pacing has been shown to increase cardiovascular mortality, incidence of heart failure (HF), worsen left ventricular (LV) function and accelerate the development of atrial fibrillation (AF). High percentage ventricular pacing and wider paced QRS in the setting of normal baseline LV ejection fractions have consistently been shown to be independent risk factors for pacing-induced cardiomyopathy. Left bundle branch pacing (LBBP) has emerged as a potential alternative pacing mechanism that may avoid LV dyssynchrony and pacing-induced LV dysfunction by mimicking native electrical conduction.
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Left bundle branch pacing lead (Select Secure 3830 lead) for heart block?
Left bundle branch pacing (LBBP) has been shown to be a safe and effective alternative to traditional pacing methods, like right ventricular pacing, especially in patients with heart failure and left bundle branch block. Studies have demonstrated that LBBP can provide synchronized heart contractions and improve heart function, potentially reducing the risk of heart failure hospitalizations.12345
Is left bundle branch pacing generally safe for humans?
How is the treatment of Left Bundle Branch Pacing different from other treatments for heart block?
Eligibility Criteria
This trial is for adults over 18 with certain types of heart block who need a lot of ventricular pacing and have an ejection fraction over 35%. It's not for those needing a defibrillator, with mechanical tricuspid valves, previous similar device attempts, pregnant women, permanent atrial fibrillation patients or those with short life expectancy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either left bundle branch pacing or standard right ventricular pacing
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Left bundle branch pacing lead (Select Secure 3830 lead)
- Right ventricular active fixation lead
Left bundle branch pacing lead (Select Secure 3830 lead) is already approved in European Union, United States for the following indications:
- Heart failure
- Cardiac resynchronization therapy
- Left ventricular dysfunction
- Heart failure
- Cardiac resynchronization therapy
- Left ventricular dysfunction
Find a Clinic Near You
Who Is Running the Clinical Trial?
McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead Sponsor
Canadian Institutes of Health Research (CIHR)
Collaborator
Heart and Stroke Foundation of Canada
Collaborator
Medtronic
Industry Sponsor
Geoff Martha
Medtronic
Chief Executive Officer since 2020
Finance degree from Penn State University
Dr. Richard Kuntz
Medtronic
Chief Medical Officer since 2023
MD, MSc